The Liver Meeting 2023-Cholestatic & Autoimmune Liver Disease SIG

Cholestatic & Autoimmune Liver Disease SIG - 3114

Video Transcription

Video Summary

The gut-liver axis is crucial in cholestatic liver disease, with FXR activation showing promise in reducing bile acid synthesis and inflammation. Microbiome manipulation and understanding bile acid interactions with immune cells are key in treating PSC. Estrogen-related FXR signaling in the gut may influence sex differences in disease progression. Research continues to explore these mechanisms for effective treatments. The role of MDR1 in protecting lymphocytes, potential substrates like tauro-CDCA, challenges of FMT in PSC patients, and use of ibotenic inhibitors in cholestatic conditions were discussed. Systemic ASPD inhibitors hold promise, with potential limitations from GI side effects. Addressing TPN cholestasis involves removing soybean lipids and considering medium chain triglycerides.

Keywords

gut-liver axis

cholestatic liver disease

FXR activation

bile acid synthesis

inflammation

microbiome manipulation

PSC

estrogen-related FXR signaling

sex differences

MDR1

tauro-CDCA

FMT

ibotenic inhibitors

ASPD inhibitors